Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  SCYNEXIS Inc    SCYX

SCYNEXIS INC

(SCYX)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/11/2019 02/12/2019 02/13/2019 02/14/2019 02/15/2019 Date
1.34(c) 1.33(c) 1.39(c) 1.37(c) 1.38(c) Last
3 152 934 2 516 530 955 754 774 914 492 687 Volume
+15.52% -0.75% +4.51% -1.44% +0.73% Change
More quotes
Financials (USD)
Sales 2018 0,28 M
EBIT 2018 -29,6 M
Net income 2018 -22,8 M
Debt 2018 -
Yield 2018 -
Sales 2019 0,17 M
EBIT 2019 -40,7 M
Net income 2019 -41,6 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 238x
Capi. / Sales2019 392x
Capitalization 66,2 M
More Financials
Company
SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078... 
Sector
Pharmaceuticals
Calendar
04/08Earnings Release
More about the company
Surperformance© ratings of SCYNEXIS Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on SCYNEXIS INC
02/07SCYNEXIS : Latest Developments in Combating Antifungal Resistance to be Discusse..
AQ
01/30SCYNEXIS : Announces Positive Interim Results from Phase 3 Open-Label FURI Study..
PR
01/24SCYNEXIS INC : Change in Directors or Principal Officers (form 8-K)
AQ
01/17SCYNEXIS : Antimicrobials Working Group Announces Updates to Leadership Team
PR
01/08SCYNEXIS INC : Completion of Acquisition or Disposition of Assets, Financial Sta..
AQ
01/03SCYNEXIS : Provides Year-end Update and Outlines Plans for 2019
PR
2018SCYNEXIS INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rul..
AQ
2018SCYNEXIS, INC. : to Present at Upcoming Investor Conferences
PR
2018SCYNEXIS : Technological Advancements Show Growth in the Hospital Acquired Infec..
PR
2018SCYNEXIS : 3Q Earnings Snapshot
AQ
More news
Sector news : Pharmaceuticals - NEC
02/15BRISTOL MYERS SQUIBB : Starboard gauges Bristol-Myers shareholder support for Ce..
RE
02/15Bayer gains full Vitrakvi rights from Eli Lilly's Loxo
RE
02/15WSJ TAX GUIDE 2019 : What Investors Need to Know -2-
DJ
02/15WSJ TAX GUIDE 2019 : What Investors Need to Know -- Journal Report
DJ
02/15WSJ TAX GUIDE 2019 : The Drug Industry -- Journal Report
DJ
More sector news : Pharmaceuticals - NEC
Chart SCYNEXIS INC
Duration : Period :
SCYNEXIS Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SCYNEXIS INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 5,81 $
Spread / Average Target 321%
EPS Revisions
Managers
NameTitle
Marco Taglietti President, Chief Executive Officer & Director
Guy MacDonald Chairman
Eric Francois Chief Financial Officer
David Angulo Gonzalez Chief Medical Officer
Ann F. Hanham Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SCYNEXIS INC186.49%66
JOHNSON & JOHNSON4.08%365 768
PFIZER-3.85%245 920
ROCHE HOLDING LTD.11.98%233 242
NOVARTIS7.19%228 685
MERCK AND COMPANY4.45%207 536